Navigation Links
Positive Results for Ophthotech's Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
Date:5/4/2009

itive to an anti-VEGF attack.

"The objective and robust response of neovascular regression is consistent with the biologic activity of E10030. I look forward to a randomized trial design to confirm the strong proof of concept data of this study," said Dr. Donald J. D'Amico, Professor and Chairman, Department of Ophthalmology, Weill Cornell Medical College, New York-Presbyterian Hospital.

"It is exciting to see our clinical trial confirm the strong preclinical data from oncology and ophthalmic studies targeting the molecules regulating pericyte and endothelial cell survival. Ophthotech will continue to devote its resources towards an accelerated development of our anti-PDGF compound," said Dr. Samir C. Patel, President and CEO of Ophthotech Corp.

Wet AMD is characterized by the abnormal growth of blood vessels (neovascularization) beneath the retina, which leak blood and fluid and can cause permanent damage to cells in the center of the retina (the macula). This form of AMD is the most severe form of the disease, and often leads to permanent vision loss.

E10030 is one of three compounds that Ophthotech is developing to treat wet and dry AMD. Additional molecular entities include an anti-C5 aptamer and volociximab, an anti-angiogenic monoclonal antibody targeting the a5B1 integrin, both currently in a Phase I study.

About anti-PDGF E10030

E10030 is an aptamer-based compound directed against PDGF-B. Pharmacology studies indicate that E10030 binds to PDGF-B with high specificity and affinity and inhibits the functions of PDGF-B both in vitro and in vivo. In preclinical studies, E10030 demonstrated the potential to regress neovascularization when used in combination with a VEGF-A inhibitor. In experiments involving models of ocular vascularization, concurrent inhibition of PDGF-B and VEGF-A signaling was superior to inhibition of the VEGF-A pathway alone.'/>"/>

SOURCE Ophthotech Corp.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
2. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
3. HIV positive and HIV negative patients have similar survival rates following liver transplant
4. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
5. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
6. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
7. Economy Got You Down? Use The Principles Of Positive Psychology
8. Standard and Poors Raises Boston Scientifics Rating Outlook to Positive
9. Recent Industry Developments Reaffirm Positive Glucose Industry Outlook
10. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
11. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Los Angeles, CA (PRWEB) May 22, 2013 ... board, The J. M. Smucker Company, and Danny ... Awards yesterday at the GS1 General Assembly and Global ... Mr. Smucker and Mr. Wegman were recognized for their ... Standards - the most broadly used supply chain standards ...
(Date:5/22/2013)... report these findings in the current online edition ... pan-European study could open up new possibilities of ... which tackle diseases before the patient,s nervous system ... group of genetic diseases of the cerebellum and ... have limited control of their muscles. They also ...
(Date:5/22/2013)... new guidelines the first in more than 35 ... for surgical patients. The recommendations, based on a lengthy ... (JHH), can potentially save the medical center more than ... , A report on the research that led up ... Anesthesiology , suggests millions of dollars a year ...
(Date:5/22/2013)... Toppik and Bosley hair fibers, two hair loss concealer products ... hair. Hair loss treatments can be a lengthy process. In ... waiting period, one can use these hair loss concealers. They ... surgery in general. , Bosley and Toppik Hair Thickening ... eliminate the appearance of balding and thinning hair. It is ...
(Date:5/22/2013)... NC (PRWEB) May 22, 2013 The 2013 ... (DSM-5) is the largest change to hit the field ... Jung Center is will help prepare for the release with ... therapists has been trained knowing no other diagnostic scheme besides ... DSM-5 diagnostic manual will be released worldwide. In honor of ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 2Health News:A pan-European study: Signs of motor disorders can appear years before disease manifestation 3Health News:Johns Hopkins rewrites obsolete blood-ordering rules 2Health News:Johns Hopkins rewrites obsolete blood-ordering rules 3Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2
... Conferring with pharmacists permits quicker changes in drugs, improved ... -- Monitoring your blood pressure at home and reporting ... keep blood pressure readings lower than standard care does, ... half of people who used this system of blood ...
... AUSTIN, TexasMechanical engineering Assistant Professor Adela Ben-Yakar at The ... "microscalpel" that destroys a single cell while leaving nearby ... for cancer, epilepsy and other diseases. , "You can ... damaging the cells above and below it," Ben-Yakar says. ...
... Brava, LLC announces a major milestone.,Since its introduction 7 ... have used the Brava Breast Enhancement System. The Brava,system ... from,Brava in the United States and through international distributors ... V. Freyre, President and CEO of Brava, "We are ...
... Cycle Would Create a ,Stampede, of Other ... WASHINGTON, June 24 As policymakers ... package, they face the decision of,either supporting ... postponing the Average Manufacturer Price (AMP) pharmacy ...
... WASHINGTON, June 24 The American Lung,Association commends ... its,passage of the Pulmonary and Cardiac Rehabilitation Act ... Patients and Providers Act of,2008, the Pulmonary and ... make life easier for millions of Americans who ...
... who goes for tests, study concludes , , TUESDAY, ... from colorectal cancer among minorities in United States may ... cultural barriers that lead to less preventative screening among ... The report, published in the June 23 issue of ...
Cached Medicine News:Health News:Going Online to Draw the Line on High Blood Pressure 2Health News:Going Online to Draw the Line on High Blood Pressure 3Health News:Laser surgery probe targets individual cancer cells 2Health News:Time for Policymakers to Choose: 'Prompt Pay' Mandate or Postpone AMP Reimbursement Cuts 2Health News:American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act 2Health News:Social, Health Care Factors Drive Colon Screen Disparities 2
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... MANALAPAN, N.J. , May 22, 2013 ... this opportunity to update shareholders about some recent company ... will expand its avenues of communication with shareholders. Integrating ... has launched a Facebook page and will post updates ... the Twitter hashtag is #medifirstusa. Says ...
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
Breaking Medicine Technology:MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Medifirst Solutions, Inc. Announces Update To Shareholders 2Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
Angled shafts, smooth jaws, polished finish....
... insertion of second generation 6 millimeter foldable ... millimeters, and is perfect for clear corneal ... rounded blades provide a secure grip of ... controlled release of the optic through a ...
Autoref / Ker N vision K 5001 has auto fogging, wide view window, near vision reading. Clear 5.6 Inch color monitor. Data screen function. SE Value display function. Quick printer with automatic cutt...
... Auto-Kerato Refractometer combines an auto-refractor, an auto-keratometer, ... all in a single, compact unit. This ... the diagnostic capabilities in one-third the space, ... the individual instruments. By implementing Topcons exclusive ...
Medicine Products: